Skip to main content

BICYCLE THERAPEUTICS PLC

For the period ended Jun 30, 2024. Filed Aug 6, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 6, 2024

BCYC$3.69-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

​​​​​​​​​​​​​
​ · ​ · Three Months Ended · ​ · Six Months Ended
​ · ​ · June 30, · ​ · June 30,
​ · 2024 · 2023 · 2024 · 2023
Collaboration revenues​$9,361​$11,397​$28,891​$16,293
Operating expenses:​​​​​​​
Research and development​40,059​39,720​74,923​71,931
General and administrative​15,949​14,788​32,331​29,276
Total operating expenses​56,008​54,508​107,254​101,207
Loss from operations​(46,647)​(43,111)​(78,363)​(84,914)
Other income (expense):​​​​​​
Interest income​7,774​812​13,398​3,741
Interest expense​​(824)​​(821)​​(1,645)​​(1,629)
Total other income (expense), net​6,950​(9)​11,753​2,112
Net loss before income tax provision​(39,697)​(43,120)​(66,610)​(82,802)
Provision for (benefit from) income taxes​115​(517)​(235)​(1,135)
Net loss​$(39,812)​$(42,603)​$(66,375)​$(81,667)
Net loss per share, basic and diluted​$(0.77)​$(1.41)​$(1.40)​$(2.71)
Weighted average ordinary shares outstanding, basic and diluted​51,992,034​30,191,693​47,276,062​30,097,234
​​​​​​​​​​​​​
Comprehensives loss:​​​​​​
Net loss​$(39,812)​$(42,603)​$(66,375)​$(81,667)
Other comprehensive income:​​​​​​
Foreign currency translation adjustment​(314)​(948)​212​(1,264)
Total comprehensive loss​$(40,126)​$(43,551)​$(66,163)​$(82,931)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.